State Key Laboratory of Oncology in Southern China, Guangzhou, China.
Eur J Clin Invest. 2013 Feb;43(2):131-40. doi: 10.1111/eci.12024. Epub 2012 Dec 7.
BRD7 is a member of bromodomain-containing protein and was found to be a cofactor of P53. Down-regulation of BRD7 has been shown in nasopharyngeal carcinoma cell lines and tissues. However, the clinical role of BRD7 in colorectal cancer remains unknown.
Real-time PCR, Western blotting analysis and immunohistochemistry were employed to examine BRD7 expression in CRC cell lines/tissues compared with normal epithelia cells/adjacent non-tumorous tissues. In addition, statistical analyses were applied to evaluate the diagnostic value and associations of BRD7 expression with clinical parameters of patient samples.
BRD7 was down-regulated in colorectal cancer cell lines and cancerous tissues compared with that in normal colon epithelial cells and adjacent noncancerous tissue samples. BRD7 protein expression was positively correlated with clinical stage (P < 0·001), T classification (P = 0·001), N classification (P < 0·001), M classification (P < 0·001) and pathologic differentiation (P = 0·008). Patients with low/none BRD7 expression had shorter overall survival time than those with higher BRD7 expression. Univariate and multivariate analyses indicated BRD7 expression was an independent prognostic factor (P < 0·001).
BRD7 may serve as a potential prognostic biomarker of human colorectal cancer.
BRD7 是溴结构域蛋白家族的成员，被发现是 P53 的共因子。鼻咽癌细胞系和组织中 BRD7 的表达下调。然而，BRD7 在结直肠癌中的临床作用尚不清楚。
采用实时 PCR、Western blot 分析和免疫组织化学方法，比较结直肠癌细胞系/组织与正常上皮细胞/相邻非肿瘤组织中 BRD7 的表达。此外，还应用统计分析评估了 BRD7 表达与患者样本临床参数的诊断价值和相关性。
与正常结肠上皮细胞和相邻非癌组织样本相比，BRD7 在结直肠癌细胞系和癌组织中表达下调。BRD7 蛋白表达与临床分期（P<0·001）、T 分类（P=0·001）、N 分类（P<0·001）、M 分类（P<0·001）和病理分级（P=0·008）呈正相关。BRD7 低表达/无表达的患者总生存时间短于 BRD7 高表达的患者。单因素和多因素分析表明，BRD7 表达是独立的预后因素（P<0·001）。
BRD7 可能是人类结直肠癌的潜在预后生物标志物。
